Pharma BD Deal Intelligence
A $1.9B all-cash acquisition that gave Sanofi Rezurock (belumosudil), the first FDA-approved treatment for chronic graft-versus-host disease, bolstering its transplant portfolio. A clean strategic fit, though the deal remains a niche add rather than a transformative bet.
Sanofi acquired Kadmon for $1.9B for US biotech company.
Sanofi to acquire Kadmon Holdings for $9.50 per share in $1.9B deal for Rezurock ROCK2 inhibitor.
Sanofi to develop Kadmon belumosudil for diffuse cutaneous systemic sclerosis after $1.9 billion buyout.
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
Sanofi acquired Kadmon Holdings for approximately $1.9 billion ($9.50 per share) in an all-cash merger, gaining Rezurock (belumosudil), an FDA-approved first-in-class treatment for chronic graft-versus-host disease (cGVHD), to strengthen its transplant portfolio.
14K US cases/yr · $1.5B Global GVHD Market (2024)
Sanofi acquired Kadmon for $1.9B for Rezurock (belumosudil, ROCK2 inhibitor) approved for cGVHD after 2+ prior lines.
Incyte (Jakafi, ~$300M GVHD) leads. Sanofi (Rezurock) 3L+. BMS (Orencia) for acute GVHD prevention.
14K US cases/yr · $1.2B US cGVHD Market (2024)
Chronic graft-versus-host disease occurs when donor immune cells attack recipient tissues after allogeneic stem cell transplant. It affects 30-70% of transplant recipients and is the leading cause of non-relapse mortality. Rezurock is first-in-class for patients failing 2+ prior lines of systemic therapy.
Rezurock (belumosudil) inhibits ROCK2, a kinase involved in immune cell differentiation and fibrosis. It is approved for adults and pediatrics 12+ after failure of 2+ prior systemic therapies. Competitors include Jakafi (ruxolitinib) and Imbruvica (ibrutinib), though Rezurock targets a different mechanism.
Sanofi completed $1.9B acquisition of Kadmon Holdings, gaining Rezurock (belumosudil), approved treatment for chronic graft-versus-host disease.
Rezurock grew steadily as only FDA-approved treatment for chronic GvHD, establishing meaningful franchise in high-unmet-need transplant setting.
CHMP issued a negative opinion on Rezurock for third-line chronic GvHD in the EU; Sanofi to seek re-examination. US franchise unaffected and strong (FY2024 net sales EUR470M, +51.6%).
Rezurock fills clear unmet need in chronic GvHD with growing revenue. $1.9B reasonable for approved rare disease drug with limited competition.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sanofi SA / Kadmon Holdings Inc. (this deal) | 2021 | $1.9B | 61 |
| Sanofi SA / Regeneron Pharmaceuticals, Inc. | 2007 | $1.0B | 97 |
| Sanofi SA / Synthelabo S.A. | 1998 | $11.0B | 84 |
| Sanofi SA / Genzyme Corporation | 2011 | $20.1B | 84 |
| Sanofi SA / Amunix Pharmaceuticals Inc. | 2021 | $1.2B | 76 |
| Sanofi SA / Genzyme Corporation | 2010 | $18.5B | 75 |
| Sanofi SA / Translate Bio Inc. | 2018 | $805M | 73 |
← Browse all deals · How we score deals
More: 2021 deals · Sanofi SA deals · Immunology deals